As the American Society of Clinical Oncology (ASCO) annual meeting continued over the weekend, Celgene Corp. made a splash with data from two Phase III studies that analysts believe will convince doctors to use Revlimid (lenalidomide) as maintenance therapy in multiple myeloma (MM). (BioWorld Today)